BTIG analyst Mark Massaro notes that earlier today, a short report was published on GeneDx (WGS), which alleges wholesale reimbursement fraud ...

Das GeneDx-Management bestätigte, dass das Unternehmen kein "Code Stacking" betreibt und angemessene CPT-Codes für Genom- und Exom-Tests abrechnet, die das Kerngeschäft darstellen. Die Analysten hoben ...

BTIG analysts stood firm on their positive stance towards GeneDx (NASDAQ:WGS), reiterating a Buy rating and a $95.00 price target for the company's stock. With analyst targets ranging from $70 to $118 ...

TD Cowen analyst Daniel Brennan maintained a Buy rating on GeneDx Holdings (WGS – Research Report) today and set a price target of $118.00. The ...

Eine Analyse von InvestingPro zeigt, dass das Unternehmen mit einem gesunden Verhältnis von kurzfristigen Vermögenswerten zu kurzfristigen Verbindlichkeiten von 2,41 eine starke Fähigkeit zur ...

Adds analyst comment. GeneDX (NASDAQ:WGS) fell 4% after a short report from Grizzly Research on the genetic testing company. Grizzly Research disclosed that it's short shares of GeneDX (NASDAQ:WGS).

Management expects GeneDx to report: Revenues of at least $299M for full year 2024, an increase of 54% year-over-year vs previous guidance was $284-$290M. Consensus $288.2M..

January 13, 2025--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported preliminary financial results for ...

GeneDx Holdings Corp. (NASDAQ:WGS – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the six brokerages that are presently covering the company, Marketbeat reports.

GeneDx Holdings (NASDAQ:WGS) expects to exceed guidance with full year 2024 revenues of at least $299M ($288.20M estimate) and adjusted gross margin of at least 64% (previous guidance was at least ...

GeneDx Holdings Corp. (NASDAQ:WGSWW – Get Free Report) was the target of a large drop in short interest in January.As of January 15th, there was short interest totalling 7,800 shares, a drop of ...

GeneDx Holdings Corp. experienced a dramatic turnaround in 2024, achieving profitability and 100x returns, driven by reduced cash burn and strategic product innovations. Key growth catalysts ...